INCR vs. CLRB, ANVS, PDSB, ADAG, EBS, IMUX, IOBT, RNAC, ANIX, and SCTL
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Cellectar Biosciences (CLRB), Annovis Bio (ANVS), PDS Biotechnology (PDSB), Adagene (ADAG), Emergent BioSolutions (EBS), Immunic (IMUX), IO Biotech (IOBT), Cartesian Therapeutics (RNAC), Anixa Biosciences (ANIX), and Societal CDMO (SCTL). These companies are all part of the "pharmaceutical preparations" industry.
Cellectar Biosciences (NASDAQ:CLRB) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.
Cellectar Biosciences received 237 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
Cellectar Biosciences' return on equity of 0.00% beat InterCure's return on equity.
Cellectar Biosciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
Cellectar Biosciences currently has a consensus target price of $20.00, suggesting a potential upside of 560.07%. Given InterCure's higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than InterCure.
In the previous week, Cellectar Biosciences and Cellectar Biosciences both had 1 articles in the media. Cellectar Biosciences' average media sentiment score of 1.00 beat InterCure's score of 0.50 indicating that InterCure is being referred to more favorably in the news media.
16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 4.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
InterCure has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
Summary
InterCure beats Cellectar Biosciences on 9 of the 14 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
